Apply for grants

Our vision is to improve people’s health and the sustainability of society and the planet


Our focus areas


Infectious diseases, diabetes, obesity and cardiovascular disease are a threat to global public health.


We must solve the climate crisis and develop tomorrow’s food production so that we can feed a growing world population in a sustainable way.

Life science ecosystem

A robust life science ecosystem is a prerequisite for scientific breakthroughs and for developing new technologies that can help to solve major societal challenges.

World events such as climate change, food shortages, global public health and a pandemic affect our focus areas. In the coming years, we will increase our efforts to help to solve these urgent societal challenges.”
Mads Krogsgaard Thomsen
Professor, CEO, Novo Nordisk Foundation

Selected projects and initiatives

Challenge Programme

The Novo Nordisk Foundation wishes to make significant contributions to the development and strengthening of the Danish research ecosystems, within research aimed at solving major challenges in health and the sustainability of society and the planet.

Partnership for Education of health Professionals (PEP)

With the Partnership for Education of Health Professionals (PEP), the Novo Nordisk Foundation takes a step towards reducing inequity in health by strengthening the education of health professionals in India, Kenya and eastern Africa.

Pandemic Antiviral Discovery (PAD)

Together with Open Philanthropy and the Bill & Melinda Gates Foundation, the Novo Nordisk Foundation has made an initial commitment of up to USD 90 million in coordinated funding towards the initiative in 2022.

Danish Centre for AI Innovation

The national centre will house one of the world’s most powerful AI supercomputers

The Novo Nordisk Foundation Vaccine Accelerator (NVAC)

Enabling the NIVI mission by providing industry-level expertise in vaccine development

Novo Nordisk Foundation Cellerator

The initiative aims to advance the cell therapy ecosystem and enable transformative treatments. 

AMR Action Fund – global initiative to combat antimicrobial resistance

Several leading pharmaceutical companies and foundations have raised USD 1 billion to launch the AMR Action Fund. The aim is to bring 2–4 new antibiotics to patients by 2030.

Coronavirus initiatives

The Novo Nordisk Foundation is supporting a number of initiatives in relation to combatting COVID-19.

Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW)

The Foundation has awarded up to DKK 2.2 billion (300 million euro) over a 10-year period for the center, which is established as a partnership between three leading research institutions.

PIG-PARADIGM – research into the intestinal resilience of piglets

The Novo Nordisk Foundation has awarded DKK 150 million (€20.1 million) for an interdisciplinary research project that may lead to a reduction in the use of antibiotics in the pig farming industry.

Our grants

The Novo Nordisk Foundation awards grants based on applications in open competition and supports a large number of different areas within health, sustainability and life science.

How to apply See our grants

About the Novo Nordisk Foundation

The Novo Nordisk Foundation is an independent Danish foundation with corporate interests. Our objectives are: 1) to provide a stable basis for the commercial and research activities of the companies in the Novo Group (Novo Nordisk A/S and Novozymes A/S (Novonesis)); and 2) to support scientific, humanitarian and social causes.


The Novo Nordisk Foundation was established on 1 June 1924

DKK 9.1 billion

In 2023, the Foundation awarded a total of DKK 9.1 billion in grants for new projects and initiatives.

Novo Holdings

The Novo Nordisk Foundation’s commercial activities are carried out by the Foundation’s fully owned subsidiary Novo Holdings. The purpose of Novo Holdings is to be a supportive owner of the Novo Group companies and to generate long-term returns on the assets of the Novo Nordisk Foundation. Novo Holdings has more than 100 active investments within the life science sector.